Honestquo Venture Podcast

Hosted by honestquo.com

Business Entrepreneurship

Website RSS feed

Episodes

Latest episode

Jan 2026

Language

EN-US

About the show

No-frills podcast delivering exclusive frameworks and actionable playbooks for CFOs, finance leaders, and founders on fundraising, capital strategy, and investor communications — insights you won’t find elsewhere. Hosted by an xGoldman Sachs banker/investor & strategic finance lead. | powered by honestquo.com | fka NeuralZen Venture Podcast | circa 2024.

Listen to episodes

60 recent

January 6, 202618 min

Andrew Gazdecki: From Bizness Apps to Acquire.com – Inside Startup Exits and Building Founder-Friendly M&A

Andrew Gazdecki, founder and CEO of Acquire.com, joins the show for a candid conversation on his journey from bootstrapping Bizness Apps in college to selling startups and creating the “world’s most founder-friendly startup acquisition marketplace.” In this episode, Andrew shares how growing up outside the Ivy League shaped his founder grit, the lessons learned building multiple companies, and why he believes sales— not pedigree— is the ultimate founder skill. He breaks down the realities of selling a SaaS business, what he wishes more founders knew about exits, and the moments when it’s time to pivot (or walk away). You’ll hear Andrew’s take on doing customer support solo during COVID, paying $240K for Acquire.com’s domain, and creating a platform that gives sellers control instead of feeling like “just another investment bank deal.” Packed with practical advice for non-technical founders, real talk on regret versus timing in sales, and unique insights on the M&A process, this episode is for anyone serious about building and selling founder-led businesses.

December 19, 202525 min

Early-Stage Biotech Investing: Inside the Mind of Yaniv Sneor

Ever wondered what it takes to invest in the cutting-edge of biotech? In this episode, we sit down with Yaniv Sneor, a serial entrepreneur turned life science angel investor, to explore the world of early-stage biotech investing.From founding and scaling companies to building a niche angel investment group, Yaniv shares insights on:The differences between public market investing vs. angel investing in biotechHow his group conducts rigorous due diligence on transformative companiesKey qualities and metrics he looks for in founders and startupsStrategies for accredited investors to navigate the life sciences landscapeThe potential for high returns and why early-stage investments matterWhether you’re an investor, entrepreneur, or just curious about the intersection of science and finance, this episode gives a rare, insider look at how angels identify and support the next generation of breakthrough therapies and devices.

September 18, 202532 min

Jordan Fliegel : From Pro Basketball to Startup Exits, Ex-Techstars MD, and Now Backing Acquisition Entrepreneurs

Jordan Fliegel: (Co-CEO of Shareholder Ventures, 5x Founder, Ex-Techstars MD) unpacks his journey from professional basketball benchwarmer to serial entrepreneur—and why he’s now helping others **buy profitable businesses** instead of starting them. **🗝️ HIGHLIGHTS YOU CAN’T MISS:** - **The $5M SBA Loan Hack:** How to acquire cash-flowing businesses with 80-90% debt (even without personal capital). - **"Pizza Dinner Growth Hacks":** How being his own first CoachUp coach + bribing coaches with pizza scaled a marketplace. - **Pro Sports → Startups:** NBA-level teamwork drills for hiring talent who outshine you. - **Why He Quit Venture Capital:** "Buying boomer-retiring businesses beats startups for 99% of entrepreneurs." - **Brutal Founder Truths:** "If you need nights/weekends totally free? **Don’t be an entrepreneur.**" **🔍 For:** First-time founders, burnt-out VCs, bankers, operators & anyone eyeing the $10T small-business transfer wave. 👉 Follow Honestquo for unscripted talks with builders.

September 17, 202518 min

From Lab to IPO: Dr. Stephen Squinto on Building Iconic Biotech Companies

Dr. Stephen Squinto — co-founder of Alexion, early Regeneron scientist, and now biotech investor at J.P. Morgan — reflects on a 40-year journey in biotech. He shares what it was like to build Alexion from scratch, lessons from clinical failures, how to spot undervalued technologies, and what most founders get wrong.We talk about the evolution of biotech from the 1980s to the AI era, the realities of drug development, and what makes a great founding team. Honest, practical, and rare insight from someone who’s done it all — from the lab bench to global scale.

September 16, 202524 min

Dr. Lydia Villa-Komaroff: The Scientist Who Engineered Insulin & Shaped Biotech

Dr. Lydia Villa-Komaroff — the Mexican American molecular biologist whose breakthrough insulin gene cloning changed medicine forever — shares her trailblazing journey. At 78, she reflects on:🔬 Pioneering the Biotech Revolution:• The cutthroat race to clone insulin in the 1970s (and the blizzard that almost derailed it ❄️).• How her team’s work birthed Genentech & Biogen — and transformed diabetes treatment worldwide.💼 From Lab to Boardroom:• Why she left Harvard to lead a startup (and mortgaged her house to save it).• Lessons on resilience: "In business, rule #1 is: Don’t run out of money."🌍 Truths on Diversity & Aging:• Why diversity isn’t "nice to have" — it’s essential for scientific breakthroughs.• Her take on immortality: "Humans shouldn’t live forever. Children bring the new ideas."• The future of biotech: AI’s role, inflammation research, and tackling Parkinson’s.A masterclass in reinvention from a woman who refused to be boxed in — by academia, age, or expectations.#Biotech #WomenInSTEM #Insulin #Aging #DiversityInScience #StartupLife #ScienceHistory

September 15, 202531 min

Harvard's Disruption Professor: Why Your "Big Idea" is WRONG (Thales Teixeira)

📍 Ex-HBS professor Thales Teixeira (consulted for Netflix, Airbnb, Facebook) reveals why startups don't need revolutionary tech to dominate markets. Learn:• The "Decoupling" secret behind Uber/Airbnb's rise 🚘• How customers—NOT tech—actually disrupt industries• Why your startup should solve "ugly" problems first• MBA myths & when NOT to hire consultants• Attention-economics in the TikTok eraFrom eye-tracking at Harvard to AI startups - get frameworks that rewrite business rules.

September 9, 202528 min

How Dr. Josep Bassaganya-Riera IPO'd Landos & Sold It to AbbVie for $200M+ and … and Is Doing It Again with NImmune

From Barcelona to Wall Street — Dr. Josep Bassaganya-Riera’s journey is nothing short of extraordinary. A veterinarian-turned-immunologist, he went on to found multiple biotech companies, take Landos Biopharma public, and lead one of the only private biotech firms with a Phase 3 asset in IBD.In this episode, we dive deep into:How Josep transitioned from academia to biotech entrepreneurship (Landos and NImmune)Raising capital in a tough biotech marketThe art of picking the right bankers for an IPOBuilding alignment with investors & the buy sideHow AI and computational immunology are reshaping drug discoveryThe lessons he learned taking a company from paper to IPO to acquisition

August 20, 202518 min

From Family Office to Fund III: Lacey Talks Search Funds, Grit, and Long-Term Thinking

In this episode of The Honestquo Venture Podcast, we sit down with Lacey Wismer, founder of Hunter Search Capital and one of the most experienced voices in the search fund ecosystem. She shares her journey from growing up in a small business family in Minneapolis to raising her third search fund. We dive into what makes a great searcher, red flags investors look out for, how deals fall apart, and why long-term thinking and self-awareness are essential in ETA (Entrepreneurship Through Acquisition). Lacey also shares insights on AI’s early impact in operations, underrated metrics, and lessons learned from both family office and institutional investing. If you’re even thinking about raising a search fund, this episode is essential listening.📍 Topics Covered:Lacey’s path from Stanford to launching Hunter Search CapitalWhat investors look for in a searcher (and red flags to avoid)The real reasons deals fall throughHow search has evolved beyond elite MBAsMetrics that matter (including why SAM > TAM)Advice for anyone exploring ETA

July 11, 202517 min

Mizuho’s Jared Holz on GLP-1s, Biotech’s Harsh Reality, and What Comes Next

In this episode, Justin sits down with Jared Holz, Managing Director and Healthcare Equity Strategist at Mizuho, to unpack the brutal truths and bright spots in today’s biotech and healthcare markets. Jared shares candid takes on why biotech has underperformed for over a decade, the dominance of Eli Lilly and Novo Nordisk in the GLP-1 space, and what it’ll take for M&A, AI, and Alzheimer's advances to move the needle.This is a fast-paced, insight-rich conversation from one of Wall Street’s most respected healthcare strategists-essential listening for biotech operators, investors, and IR professionals.Highlights include:Why biotech indices are brokenGLP-1s: Obesity, Alzheimer’s, and cardiovascular upsideM&A trends: Who’s getting bought, and whyHow Big Pharma views China dealsThe reality behind AI in drug discoveryTips for biotech IR and C-suite commsWhat retail investors keep getting wrongThe looming $400B patent cliff opportunity

July 9, 202518 min

$200B Patent Cliff, China Deals & Biotech’s Next Big Wave — Robert Darwin from Sidley Austin Breaks It Down

Big Pharma’s about to lose $200 billion in drug revenue — and the race to replace it is reshaping biotech worldwide.On this episode, Robert Darwin, Senior Partner at global law firm Sidley Austin, joins us to explore:Why pharma’s writing massive M&A checks againHow China is emerging as a leading hub for drug innovationEurope’s strengths—and where it still needs to catch upWhat’s stalled IPO markets — and what could kickstart them againWhere the new biotech funding is really coming from (it might surprise you)Plus: Robert offers his straightforward insights on FDA developments, pricing politics, and why today’s science feels straight out of “Star Trek.”If you’re in biotech, finance, or just curious about the industry’s future, this conversation is for you.🎧 Hit play now and stay ahead of the curve.